Low Vision Intervention Trial II (LOVIT II): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Low Vision Intervention Trial II (LOVIT II) (NCT00958360), a randomized phase 2 study. The primary outcome is Comparison of Changes in Visual Reading Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire.

2. Clinical Question

The clinical question concerns the difference between two rehabilitation service approaches, not rehabilitation compared with no care. Both groups received an examination and low vision devices; the intervention group also received therapy and homework. The primary outcome focuses on reported visual reading ability over the four-month follow-up. A higher subscale score means better ability or less difficulty with activities. The trial also assessed changes in mobility, visual information processing, visual motor skills, and overall visual ability. Those additional outcomes provide related but distinct views of visual functioning; they do not replace the prespecified primary question. The registry record does not report the primary outcome’s clinically important difference or a threshold for interpreting an individual change as meaningful.

3. Trial Design

LOVIT II is listed as a Phase 2, randomized, single-masked, parallel-group trial. The registry record gives an enrollment of 323 and a status of completed. The study began in 2010-08, and primary completion was recorded as 2015-07. The sponsor is the VA Office of Research and Development.

Participants were assigned to interdisciplinary low vision rehabilitation or basic low vision care. The groups were analyzed as separate parallel arms: 163 participants were included in the reported interdisciplinary group results and 160 in the basic-care group results. The listed intervention descriptions distinguish the groups by whether low vision therapy and assigned homework were included, in addition to the examination and devices common to both approaches.

Single masking is recorded, but the registry record does not identify which people were masked or describe how masking was maintained. The method used to generate the allocation sequence, allocation concealment procedures, and any stratification factors are not reported in the registry record. The trial’s own sample-size justification, original design assumptions, and plans for interim analyses are also not reported in the registry record.

The primary outcome was change from baseline to four months in visual reading ability, measured using the 48 Item VA Low Vision Visual Functioning Questionnaire. Four other changes measured with the same questionnaire were listed as secondary outcomes. A two-sided t-test is the analysis method recorded for the primary comparison. The registry record does not report a fuller statistical analysis plan, including the intended handling of missing outcome data or the analysis population definition.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 2,051 patients were screened, of whom 1,728 were excluded (1,706 ineligible per chart review and 22 ineligible after screening).

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Comparison of Changes in Visual Reading Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire, measured over changes from baseline to 4 months later.

The primary endpoint is the mean change from baseline to four months in the Visual Reading Ability subscale of the 48 Item VA Low Vision Visual Functioning Questionnaire. The scale ranges from 0 to 3.5 logits, described in the registry record as log odds ratio units. A higher score indicates better ability or less difficulty performing activities. The endpoint therefore summarizes change in a specific aspect of visual functioning rather than visual acuity alone.

Using change over a stated follow-up period lets the comparison focus on how participants’ reported reading ability shifted during the trial. Comparing the group means describes the average change in each randomized group, while the difference in means describes the contrast between those averages. The endpoint is continuous, so its summary includes a mean and standard deviation rather than a count of participants who did or did not meet a threshold.

The questionnaire also posted the mobility, visual information processing, visual motor skills, and overall visual ability outcomes. Those measures address related domains, but visual reading ability was the primary endpoint named in the registry record. The record does not report a threshold for a clinically meaningful change, nor does it explain how a particular logits difference should be interpreted for an individual participant. Statistical evidence about the group average should therefore not be treated as a direct measure of individual benefit.

7. Results Posted in the Registry

• Basic Low Vision Care Group: mean 0.95 versus 1.29 on control; difference -0.34 (95% CI -0.68 to 0.00), standardized effect d = -0.22; z-test p = 0.051.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Comparison of Changes in Mobility From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Basic Low Vision Care Group: mean 0.12 versus 0.31 on control; difference -0.19 (95% CI -0.44 to 0.06), standardized effect d = -0.16; z-test p = 0.139.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Basic Low Vision Care Group and the control. The interval gives the range of effects that remain compatible with the data.

Comparison of Changes in Visual Information Processing From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Basic Low Vision Care Group: mean 0.40 versus 0.67 on control; difference -0.27 (95% CI -0.53 to -0.01), standardized effect d = -0.23; z-test p = 0.038.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Basic Low Vision Care Group than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Comparison of Changes in Visual Motor Skills From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Basic Low Vision Care Group: mean 0.40 versus 0.77 on control; difference -0.37 (95% CI -0.66 to -0.08), standardized effect d = -0.28; z-test p = 0.013.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Basic Low Vision Care Group than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The trial lists four secondary questionnaire outcomes covering mobility, visual information processing, visual motor skills, and overall visual ability. Their estimates do not all convey the same degree of certainty. The mobility comparison’s recalculated interval includes no difference, while the recalculated intervals for visual information processing and visual motor skills are below zero for basic care minus interdisciplinary rehabilitation. The registry record lists overall visual ability as a secondary outcome, but no corresponding posted result is included among the secondary results available for comparison.

These findings provide context around the primary reading-ability result because they concern other aspects of visual functioning measured with the same questionnaire and over the same period. They do not overturn or replace the primary result. Differences across domains can occur, and the registry record does not report a single combined measure that would make the secondary outcomes equivalent to the primary endpoint.

The secondary p-values are unadjusted in the recalculations. When several outcomes are examined, the chance of at least one apparently notable result can increase, even if there is no underlying effect for any outcome. General statistical practice may address this through a prespecified multiplicity strategy, but a correction or testing hierarchy is not reported in the registry record. The secondary findings should consequently be treated as less conclusive than a single prespecified primary analysis and interpreted as exploratory evidence rather than standalone confirmation.

The registry record reports five outcome measures and posts four secondary outcome results. The reason a result for overall visual ability is not posted is not reported in the registry record. Nor does the record explain whether the listed secondary outcomes were prioritized, whether all were analyzed as planned, or how missing observations affected their estimates. These omissions limit the strength of conclusions that can be drawn from the pattern across secondary domains.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Comparison of Changes in Mobility From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire
• Comparison of Changes in Visual Information Processing From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire
• Comparison of Changes in Visual Motor Skills From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire
• Comparison of Overall Visual Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is continuous: each participant’s change is represented by a score on the questionnaire’s visual reading ability subscale. For a continuous outcome, a common summary is the mean change in each group and the difference between those means. The mean describes the center of the group’s observed scores, while the standard deviation describes how dispersed those scores are around the mean.

What does the mean difference represent?

The displayed contrast is basic low vision care minus interdisciplinary low vision rehabilitation. Its estimate is -0.34 logits. The negative sign indicates that the basic-care group’s mean change was lower than the interdisciplinary group’s mean change in the posted comparison. The sign depends on the order of subtraction; reversing the order would reverse the sign without changing the underlying distance between group means. The direction must therefore be read together with the group labels and the scale’s interpretation, where higher scores indicate better ability or less difficulty.

What does the t-test assess?

The registry record lists a two-sided t-test for the primary comparison. In general, a two-sided test assesses whether the group means differ in either direction, rather than testing only whether one named group has a higher mean. The test uses the observed mean difference relative to its uncertainty under the test’s assumptions. Its p-value describes how compatible the observed data are with a null model of no group difference; it is not the probability that the null model is true. The registry record does not report enough detail to determine whether any adjustment or additional modeling was used beyond the listed test.

The recalculated comparison uses the posted group means, standard deviations, and sample sizes to obtain an unadjusted estimate and interval. It is a summary-statistic re-calculation, not a replacement for a full participant-level analysis. The posted primary analysis is a two-sided t-test, and the recalculated p-value is close to, but not exactly the same as, the registry-reported p-value. No discrepancy flag is recorded. The registry’s reported analysis remains an important reference because the registry record does not give the participant-level data or a complete analysis specification.

Why does the spread of scores matter?

Standard deviations help describe how much individual outcomes vary within each group. When variability is large compared with the difference in group means, the mean contrast is estimated less precisely unless the study has enough participants to offset that variation. The primary group standard deviations, 1.66 and 1.46 logits, are appreciably larger than the absolute size of the mean difference. This is one reason the group contrast should be interpreted with its interval rather than by comparing the two means alone.

The recalculation reports a pooled standard deviation of 1.564 logits. In general, a pooled standard deviation combines within-group variability into a common scale for describing a standardized contrast. Its use is a statistical summary; it does not imply that every participant’s change follows the same pattern. The standardized effect in the recalculation is -0.217. This value expresses the contrast relative to the pooled variability, but it does not itself define clinical importance. No minimal clinically important difference is reported in the registry record.

Why can over-dispersion matter?

General statistical explanation: over-dispersion occurs when observed variability is greater than a model assumes. If a model understates variability, its standard errors can be too small and its intervals too narrow, which can make evidence appear more precise than it is. For this primary outcome, the registry record describes a continuous measure summarized with means and standard deviations, and the recalculation uses those posted values. The registry record does not report a specific over-dispersion assessment or indicate that an over-dispersion correction was used. It would not be appropriate to assume that such a correction was part of the trial analysis.

What is the role of randomization and masking?

Random allocation is intended, in general, to make the treatment groups comparable on average at the start of a trial, including on factors that are not measured. It does not guarantee that every characteristic will be balanced in a particular trial. The registry record identifies the study as randomized but does not report baseline comparisons or the allocation procedure. It lists single masking, without stating who was masked. The available details therefore support describing the recorded design, but not making additional claims about how allocation or masking was implemented.

None of these methods makes the result a guarantee about an individual participant. The primary comparison is an estimate of an average difference, accompanied by uncertainty. The posted values do not describe the full distribution of participant outcomes, and the registry record does not provide information needed to assess every aspect of the analysis, such as missing-data handling or adjustment for multiple outcomes.

11. Confidence Intervals and Precision

The recalculated interval for the primary mean difference extends from -0.681 to 0.001 logits. It includes zero, the value that represents no difference in group means. The interval therefore indicates that the data are compatible with a range of contrasts, including a difference favoring interdisciplinary rehabilitation and a value very close to no difference. The registry record does not state the confidence level for this interval, so no confidence percentage is assigned.

In general, a confidence interval expresses uncertainty around an estimate under the assumptions of the method used. A narrower interval indicates greater precision about the estimated contrast; a wider interval leaves more possible values compatible with the data. The interval is not a range containing a known proportion of individual participant outcomes, and it does not indicate that every value inside it is equally plausible.

The primary estimate is -0.34 logits, and the interval reaches close to zero on its upper end. That proximity explains why a small change in the estimate or its uncertainty could affect whether the interval crosses zero. It does not justify treating the estimate as either a definitive difference or proof of no difference. The posted group sizes and variability contribute to the precision, but the registry record does not give the participant-level information needed to examine the interval under alternative models or assumptions.

Precision and clinical importance are separate questions. Even a precise estimate would need an interpretable threshold to establish whether the size of a difference matters in practice; such a threshold is not reported in the registry record. Conversely, an uncertain estimate does not show that the groups are identical. The appropriate reading is that the estimated mean contrast is modest in scale and remains uncertain, with the interval including no difference.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are participants per arm, not total participants or total events. They use a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is set as a stated fraction of the observed effect. The registry record does not report the trial’s own original sample-size assumptions or justification.

The 80% power column describes the planned number of participants per arm that, under those planning assumptions, would give an 80% chance of detecting the specified effect if that effect were the true one. The 90% power column applies the same idea with a higher target chance of detection, which generally requires more participants. These are planning illustrations based on the observed effect, not a reconstruction of the study’s design.

The rows consider planning for 100%, 75%, and 50% of the observed effect. Smaller target effects require more participants because they are harder to distinguish from random variation. For example, the primary-outcome planning figure for 80% power is 333 participants per arm when planning for 100% of the observed effect, 591 for 75%, and 1,329 for 50%. These values are not the number enrolled or analyzed in the trial.

This is not observed power. Observed power is not a substitute for interpreting the estimated effect and its uncertainty after a study has been completed. The trial enrolled 323 participants, whereas these planning counts illustrate hypothetical future planning under stated assumptions. They should not be read as evidence that the completed trial was inadequately or adequately designed, since its own original design assumptions are not reported in the registry record.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.340; pooled standard deviation σ = 1.564.
2. n = 2 × (1.96 + 0.842)² × 1.564² / -0.340² = 332.2, rounded up to 333 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.34                      # observed difference in means
sigma <- 1.56413422948623                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(958360)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 333 (80% power), 445 (90% power)
 75% of observed effect: n per arm = 591 (80% power), 791 (90% power)
 50% of observed effect: n per arm = 1,329 (80% power), 1,780 (90% power)
power.t.test: 333.2 
Simulated power at n = 333 per arm: 0.798 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry record reports a two-sided t-test for the primary comparison with p = 0.05. The unadjusted recalculation from the posted group summaries gives p = 0.051 and a mean difference of -0.34 logits. The p-values are close but not identical. The registry record does not report enough detail to identify the reason for the small difference, so it should not be attributed to rounding, a specific model, or another procedure without documentation.

The recalculated estimate and interval are a transparent summary-statistic analysis, not a substitute for the sponsor’s analysis. The sponsor’s reported result should be read as the trial’s recorded analysis; the recalculation is useful for seeing how the posted means, standard deviations, and sample sizes relate to the estimated contrast and its precision. Neither p-value should be interpreted in isolation from the estimate and interval.

The registry record does not provide a numerical sponsor-reported mean difference or interval for this primary outcome. It therefore does not support a direct comparison between sponsor-reported and recalculated effect estimates. The reported t-test result and the recalculated summary-statistic result answer closely related questions, but their information and level of detail differ.

15. Multiplicity, Missing Data and Analysis Populations

The registry record lists one primary outcome and four secondary outcomes. It reports a two-sided t-test for the primary analysis and lists analyses for the posted secondary outcomes, but a multiplicity adjustment, testing hierarchy, or other family-wise error strategy is not reported in the registry record. Without that information, the secondary p-values should be understood as unadjusted results. Testing several outcomes can increase the chance of at least one result appearing statistically notable by chance, so the secondary results carry less evidential weight than the primary analysis.

The registry record does not report how missing questionnaire responses or participants without a four-month measurement were handled. It does not state whether the analysis used complete cases, imputation, a repeated-measures model, or another approach. The group counts associated with the posted outcome summaries are 163 and 160, but those counts alone do not establish whether every randomized participant contributed the primary outcome or whether any data were missing.

The analysis population is not described in detail. The registry record does not specify whether the primary analysis followed an intention-to-treat principle, whether participants were analyzed according to assigned group, or whether exclusions were made after randomization. The reasons for any difference between enrollment and outcome-analysis counts are not reported in the registry record. Those details matter because missing data and post-randomization exclusions can affect how well the comparison preserves the benefits of random allocation.

Interim analyses, stopping rules, and the full prespecified statistical plan are not reported in the registry record. The available information does not establish that these procedures were absent; it establishes only that they are not described in the registry record. These gaps constrain assessment of selective reporting, analysis choices, and the robustness of the reported estimates.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: non-study related prolonged hospitalization (5.6%), non-study related death (5.0%).

The registry record lists serious adverse events affecting 27 of 163 participants in the interdisciplinary rehabilitation group and 29 of 160 participants in the basic-care group. Other, non-serious adverse events are listed as affecting 10 of 163 and 1 of 160 participants, respectively. These are participant counts in the record; they should not be converted into a claim about the cause of an event or a difference in treatment safety without further information.

The top serious adverse event terms listed are “Non-study related Prolonged Hospitalization” at 5.6% and “Non-study related Death” at 5.0%. The registry record does not specify the group attribution or denominator for these terms in the information recorded. Death counts by group are not reported in the registry record.

Serious adverse event counts are not the same as a complete account of all safety outcomes, event timing, severity, or relatedness. The record’s descriptions label the listed hospitalization and death terms as non-study related, but do not provide further case-level detail. These figures describe what was recorded; they do not establish that an intervention caused or prevented an event.

17. What the Result Does, and Does Not, Mean

The primary comparison estimates a difference in average change in visual reading ability over four months between two forms of low vision care. The interdisciplinary group had a higher posted mean change than the basic-care group, and the recalculated contrast is expressed as basic care minus interdisciplinary rehabilitation. The interval includes no difference, so the estimate remains uncertain rather than establishing a clear separation between group averages.

The result does not mean the groups were identical. An interval that includes zero can still contain values representing a difference in either direction. Nor does the point estimate establish that the average difference is important to participants: the registry record does not report a clinically meaningful threshold for the questionnaire scale. The data describe group means and uncertainty, not an individual prediction or guarantee.

The comparison is between a service package that included examination, devices, therapy, and homework and a package that included examination and devices without therapy or assigned homework. It cannot isolate the effect of therapy from the effect of homework or other features of how the services were delivered. Both approaches included low vision examination and devices, so the trial does not compare the interdisciplinary program with no low vision care.

The findings apply directly to the trial’s recorded population and follow-up: veterans with macular diseases and best corrected visual acuity from 20/50 to 20/200, with the primary outcome measured at four months. The registry record does not report longer-term primary results or a clinically meaningful change threshold. Generalization beyond the enrolled population or the measured follow-up therefore requires evidence not contained in this record.

Finally, the primary outcome is one of several questionnaire domains. Secondary findings can add context, but unadjusted analyses across multiple outcomes have greater risk of chance findings. The most defensible interpretation remains anchored to the primary endpoint, its estimated contrast, and its uncertainty, while recognizing that details about missing data, multiplicity, and the full analysis plan are not reported in the registry record.

18. Why This Trial Matters Statistically

This trial illustrates why a group mean difference, its interval, and a p-value should be read together. The primary estimate points toward a higher average change in the interdisciplinary group, but the interval includes no difference and the recalculated p-value is close to the registry-reported value. Neither a point estimate nor a threshold-focused reading of the p-value fully captures that uncertainty.

It also illustrates the importance of the comparison being made. Participants in both groups received low vision examination and devices, while the interdisciplinary group additionally received therapy and homework. The statistical contrast concerns these two care packages as recorded; it does not isolate individual components. A clear description of the comparator is essential before interpreting an effect estimate.

The trial also has several questionnaire outcomes. Results across related domains can enrich understanding, but multiple unadjusted tests make isolated secondary findings less secure. A prespecified strategy for primary and secondary testing helps readers distinguish confirmatory evidence from exploratory patterns. Such a strategy is not reported in the registry record.

Finally, planning figures based on an observed effect are useful for illustrating how target effect size and desired power affect future sample-size planning. They do not reveal the original design rationale or retrospectively certify the trial’s power. The registry record’s missing details on the original sample-size justification, missing-data approach, and analysis populations demonstrate why transparent reporting is part of statistical interpretation, not an administrative extra.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific details needed to fully assess the result are not reported in the registry record. These include the original sample-size justification, the full statistical analysis plan, the analysis population, the handling of missing outcomes, and any multiplicity strategy for secondary endpoints. The registry record also does not report interim analyses or stopping rules. These omissions limit assessment of whether the posted analyses followed a prespecified plan.

The record identifies the study as single-masked but does not state who was masked or how masking was maintained. It identifies randomization but does not describe sequence generation or allocation concealment. These details are relevant to evaluating the conduct of a randomized trial; their absence from the record does not establish that the procedures were not used.

The primary result is based on a continuous questionnaire score, but no clinically meaningful difference threshold is reported. The record does not provide the participant-level score distribution, the number with improvement or worsening, or an account of missingness by group. As a result, the average contrast cannot describe how outcomes varied among individuals or how sensitive the estimate might be to missing data.

The posted comparison concerns a four-month outcome and a specific population of veterans with macular diseases and best corrected visual acuity from 20/50 to 20/200. The registry record does not provide a longer-term primary outcome result or further detail sufficient to judge applicability to populations outside that description. The intervention also combines therapy and homework with other service features, so this comparison cannot identify which component accounts for any observed difference.

Finally, the primary sponsor-reported analysis gives a p-value but no numerical estimate or interval in the recorded result. The summary-statistic recalculation adds an estimate and interval, but it cannot reproduce a full participant-level analysis. Both limitations should inform how confidently the numerical results are interpreted.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Low Vision Intervention Trial II (LOVIT II) — NCT00958360.
• Registry record last updated 2016-08-25; status last verified 2016-07.
• Results first posted 2016-08-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

LOVIT II was a completed Phase 2, randomized, single-masked, parallel-group trial sponsored by the VA Office of Research and Development. It enrolled 323 veterans with macular diseases and compared interdisciplinary low vision rehabilitation with basic low vision care.

The primary outcome was change from baseline to four months in visual reading ability measured with the 48 Item VA Low Vision Visual Functioning Questionnaire. Mean changes were 1.29 logits in the interdisciplinary group and 0.95 logits in the basic-care group. The recalculated mean difference, basic care minus interdisciplinary rehabilitation, was -0.34 logits, with an interval that included zero. The registry-recorded two-sided t-test reported p = 0.05; the recalculated unadjusted p-value is 0.051.

Four secondary outcomes were listed, and the record includes results for four domains, though overall visual ability is named without a corresponding posted result in the recorded secondary results. The record does not report a multiplicity strategy, missing-data approach, full analysis population, or original sample-size justification. The results describe average change at the stated follow-up and do not establish individual outcomes or a clinically meaningful threshold.